Edition:
United States

Vrinda Manocha

Synergy Pharma constipation drug succeeds in trial

Apr 30 2014

Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.

Lexicon Pharma's diabetes drug successful in mid-stage study

Apr 14 2014

Lexicon Pharmaceuticals Inc said its experimental drug to treat diabetes reduced the use of insulin at meal times in a mid-stage study of patients with type 1 diabetes, sending the company's shares up as much as 17 percent.

Alkermes to seek schizophrenia drug approval after trial success

Apr 08 2014

Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent.

FDA finds contaminated drug ingredient at GSK Ireland plant

Apr 01 2014

The U.S. Food and Drug Administration found that a drug ingredient manufactured at a GlaxoSmithKline Plc plant in Ireland was contaminated and said the company did not take sufficient action to resolve the problems.

Prana drug fails Alzheimer's study; shares plunge

Mar 31 2014

Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.

Merck names Baxter exec as CFO

Mar 27 2014

Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.

Insmed's shares recover as analysts highlight positive trial data

Mar 26 2014

Insmed Inc's shares plunged after its experimental drug to treat a form of bacterial lung infection failed the main goal of a trial, but the stock clawed back much of its early losses after analysts said positive secondary data was more relevant.

Endocyte shares soar after cancer drug gets EU backing

Mar 21 2014

Endocyte Inc's shares more than doubled after the company said its cancer drug was recommended for conditional approval in Europe for ovarian cancer and that the drug improved survival rates in lung cancer patients.

With eye on tax rates, Horizon Pharma buys Ireland's Vidara

Mar 19 2014

Horizon Pharma Inc said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million (£397.09 million), the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

With eye on tax rates, Horizon Pharma buys Ireland's Vidara

Mar 19 2014

Horizon Pharma Inc said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million, the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

World News